Cervical Length, fFN, and Serum Biomarkers: Comparing Preterm Birth Prediction Tools

Spontaneous preterm birth affects approximately 9.9% of pregnancies globally and remains the leading direct cause of neonatal mortality.¹ In the United States alone, approximately 377,000 preterm births were recorded in 2023.² Yet despite decades of research, no single prediction tool reliably identifies every woman at risk of delivering early.

Clinicians today have access to three distinct categories of tools: cervical length (CL) measurement, fetal fibronectin (fFN) testing, prior obstetric history, and serum biomarker panels. Each serves a different clinical purpose, operates in a different gestational window, and performs best in a different patient population. Understanding how they compare is essential for applying them appropriately.

Why Preterm Birth Is So Difficult to Predict

Preterm birth is not a single condition. It is an outcome driven by multiple overlapping biological pathways, including cervical insufficiency, intrauterine infection and inflammation, uterine overdistension, immune dysregulation, placental dysfunction, and idiopathic mechanisms that have gaps in understanding.³ Any given case may involve one or several of these simultaneously, and the relative contribution of each pathway varies from patient to patient.

This multifactorial nature has a direct clinical implication: tools designed to detect one mechanism of preterm birth will likely miss cases driven by another. A test sensitive to cervical shortening will not capture infection-driven risk before structural changes occur. A tool calibrated to inflammatory markers may not reflect cases where cervical insufficiency is the primary driver.

This also explains why terminology matters. Screening, prediction, and diagnosis are distinct goals. Screening identifies risk before symptoms arise. Prediction quantifies the probability of a specific outcome. Diagnosis confirms active pathology. The three tools discussed here do not all do the same thing and conflating them can lead to misapplication.

Cervical Length Measurement

Cervical length (CL) screening via transvaginal ultrasound is one of the strongest traditional predictors of spontaneous preterm birth. ⁴ Transvaginal measurement is the gold standard for accuracy in CL screening, outperforming transabdominal assessment, particularly in women with obesity or an unfavorable cervical position.⁵

The predictive power of a short cervix is strong: in population-based screening studies, a very small population of women with a cervical length <15 mm, account for a disproportionately large share of early preterm births.⁴ That concentration of risk within a small, identifiable subgroup is precisely what makes CL screening clinically valuable.

For women with a prior preterm birth, serial CL screening from 16 to 24 weeks is recommended. A CL of 25 mm or less at 16–18 weeks in this population carries a relative risk of 3.3 for recurrent preterm birth.⁶

When CL screening identifies elevated risk, it directly informs intervention: progesterone supplementation and, in selected cases, cervical cerclage. Practical constraints apply. CL screening requires a trained sonographer and is most informative between 16 and 24 weeks. It also only identifies structural risk, not the underlying biological processes that precede cervical change.

Prior Obstetric History

A prior spontaneous preterm birth is the single strongest risk factor for a recurrence, and unlike the other tools discussed here, it requires no testing, no gestational window, and no cost. It is known at the first prenatal visit.⁷

The risk is not fixed. It rises with each additional prior preterm birth, and it climbs further the earlier the previous delivery occurred; a subsequent term birth measurably lowers recurrence risk going forward. This is precisely why a documented prior preterm birth is what triggers the serial cervical length surveillance described above, and it increasingly informs candidacy for earlier biomarker-based risk assessment as well.^6,7

Fetal Fibronectin Testing

Fetal fibronectin (fFN) is best understood as a downstream triage tool for women who are already presenting with symptoms consistent with preterm labor. Its clinical role is not prediction in the proactive sense. It is used to help determine whether a symptomatic patient is actually in preterm labor, or whether her symptoms are a false alarm that does not require intervention.

The test is medically indicated for symptomatic women between 24 and 35 weeks with intact membranes and less than 3 cm dilation.⁸ Its most clinically important value is the negative result: a negative fFN carries approximately a 96% negative predictive value for delivery within the next two weeks.⁸ This matters because contraction-based preterm labor diagnosis has a false positive rate of up to 50%,⁹ and fFN provides a reliable clinical gate for avoiding unnecessary hospitalization and intervention.

A positive result is more complicated. A positive fFN has a positive predictive value of 15%–40%¹⁰, meaning most women who test positive will not deliver preterm within two weeks.

Routine fFN screening in asymptomatic women is classified as experimental/investigational and is not indicated for that population.⁸

One counterintuitive finding: a 2021 systematic review found that combining fFN with cervical length measurement does not improve prediction accuracy in symptomatic women.⁶

Serum Biomarker Testing: A Different Clinical Category

Serum biomarker panels represent a fundamentally different approach to preterm birth prediction. Rather than assessing structural changes or managing active symptoms, they analyze proteins in maternal blood to identify biological risk signals, and they do so earlier in pregnancy, before symptoms or structural changes have appeared.

This early window is clinically significant. Between approximately 16 and 22 weeks, cervical length measurement has limited utility for women who are asymptomatic and have not had a prior preterm birth. Before 24 weeks, fFN is not indicated at all. Serum biomarker testing addresses this gap: the period when risk is developing at the molecular level, but before traditional tools can detect it.

The PreTRM test is a blood-based prognostic test that uses protein biomarkers to predict spontaneous preterm birth risk in this earlier window. Validation studies have demonstrated that PreTRM can identify elevated risk for spontaneous preterm birth in asymptomatic pregnancies during the mid-trimester, when traditional clinical tools have limited predictive performance.¹¹

Clinical utility research (PAPR study) has further demonstrated how PreTRM-guided risk stratification can be integrated into prenatal care pathways, supporting earlier surveillance and more targeted intervention strategies for patients identified as high risk.¹¹

Is your practice capturing risk before symptoms appear? Learn how PreTRM fits into a comprehensive preterm birth prevention strategy.

A Clinical Framework for Choosing the Right Tool

These three categories of tools are not competing, but rather, serve different patient populations at different gestational windows.

Scenario	Best Tool
Asymptomatic, prior PTB or high-risk	Cervical length screening, 16-24 weeks
Symptomatic threatened preterm labor	fFN for triage
First-trimester risk stratification, no symptoms	Serum biomarker panel (varies by clinical availability)

The most critical clinical gap occurs prior to 22 weeks in asymptomatic women. During this period, cervical length is typically not yet informative for most patients, and fetal fibronectin (fFN) remains contraindicated.

This is the window in which serum biomarker testing provides unique clinical value, enabling earlier identification of elevated risk while meaningful intervention opportunities are still available.

What This Means for Clinical Practice

The shift this represents in prenatal care is meaningful: from reactive management, which responds to symptoms after they appear, to a more individualized, risk-based approach that aims to identify patients at increased risk earlier in pregnancy. ACOG emphasizes that preterm birth is a multifactorial condition and that care should be tailored based on patient-specific risk factors and clinical findings, rather than a one-size-fits-all approach.⁷

Earlier identification of elevated risk supports this individualized framework by expanding the window in which clinicians may consider interventions such as progesterone, cerclage, enhanced surveillance, or care pathway adjustments.

There is also a value-based care dimension to this approach. ACOG recognizes that screening and prevention strategies should be applied in a manner that aligns with patient risk and clinical context, reflecting the broader principle of targeted care. Universal application of intensive prenatal monitoring is not always practical or necessary. More precise risk stratification enables resources to be directed toward patients most likely to benefit, helping to reduce unnecessary intervention in lower-risk populations while supporting more intensive management for those at higher risk. Emerging clinical utility data suggest that risk-guided care pathways may improve outcomes while reducing downstream burden associated with preterm birth.⁷

These tools are best understood as complementary components within a longitudinal, individualized care strategy rather than isolated decision points. Early risk assessment approaches may help inform initial stratification, while cervical length monitoring provides insight into structural changes in the midtrimester, and fFN can support triage decisions in symptomatic patients later in pregnancy. Together, these modalities align with ACOG’s emphasis on using appropriate tools at the appropriate time, based on evolving clinical context, to support more personalized care across gestation.

Frequently Asked Questions

What does a short cervix actually mean for preterm birth risk?

A short cervix, particularly a transvaginal measurement below 15 mm, is strongly associated with preterm birth, especially in asymptomatic women.⁴ It is a risk marker, not a guarantee. Most women with a short cervix will not deliver before 37 weeks, but the statistical risk is significantly elevated.

Why isn’t fetal fibronectin used for routine screening in asymptomatic women?

Fetal fibronectin’s positive predictive value in asymptomatic populations is too low to make routine screening clinically useful. A positive result would prompt intervention for many women who would not deliver preterm, causing potential harm without benefit.⁸

What is the difference between fetal fibronectin and a serum biomarker test?

They serve entirely different clinical functions. fFN is a triage tool for symptomatic women. A serum biomarker test, like PreTRM, identifies molecular risk signals earlier in pregnancy before symptoms or structural changes appear.¹¹

Does combining cervical length measurement with fFN improve prediction accuracy?

No. A 2021 systematic review found no improvement in predictive accuracy when combining fFN with cervical length compared with single-method testing in symptomatic women.⁶

Is there a serum biomarker test for spontaneous preterm birth available now?

Yes. The PreTRM test is a clinically validated, commercially available blood-based prognostic test for spontaneous preterm birth risk prediction. Validation studies demonstrate its ability to identify elevated risk in asymptomatic pregnancies during the mid-trimester.¹¹ Clinical utility studies further show how this information can be used to guide prenatal care decisions.¹¹

Learn more about PreTRM’s clinical evidence or how to integrate PreTRM into your practice.

Conclusion

Effective preterm birth prediction requires matching the right tool to the right patient at the right gestational window. Cervical length measurement is the strongest structural predictor for asymptomatic women in the second trimester.⁴ Fetal fibronectin is a reliable triage tool for symptomatic women, with high negative predictive value reducing unnecessary intervention.⁸ Serum biomarker testing addresses the earliest clinical window, identifying biological risk before symptoms or structural changes occur.¹¹

As earlier risk stratification becomes more integrated into prenatal care, the opportunity to shift from reactive management to truly predictive care is here.

References 

1. Ohuma EO et al. National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis. Lancet. 2023 Oct 7;402(10409):1261-1271. doi: 10.1016/S0140-6736(23)00878-4.
2. Centers for Disease Control and Prevention. FastStats: Birthweight and Gestation. Accessed June 24, 2026. https://www.cdc.gov/nchs/fastats/birthweight.htm
3. Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes; Behrman RE, Butler AS, editors. Preterm Birth: Causes, Consequences, and Prevention. Washington (DC): National Academies Press (US); 2007. Chapter 6, Biological Pathways Leading to Preterm Birth. Available from: https://www.ncbi.nlm.nih.gov/books/NBK11353/
4. Society for Maternal-Fetal Medicine (SMFM), Biggio J, SMFM Publications Committee. SMFM Consult Series #70: Management of short cervix in individuals without a history of spontaneous preterm birth. Am J Obstet Gynecol. 2024 Aug;231(2):B2-B13.
5. Westerway S, et al. Cervical length measurement: comparison of transabdominal and transvaginal approach. Australas J Ultrasound Med. 2015. PMID: 28191237
6. Dehaene I, Lorthe E, et al. Eur J Obstet Gynecol Reprod Biol. 2021;258:394-401. doi:10.1016/j.ejogrb.2021.01.020
7. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 234: Prediction and Prevention of Spontaneous Preterm Birth. Obstet Gynecol. 2021 Aug;138(2):e65-e90.
8. Dos Santos F, et al. Accuracy of fetal fibronectin for assessing preterm birth risk in asymptomatic pregnant women: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018 Jun;97(6):657-667. doi: 10.1111/aogs.13299
9. Kiefer D, et al. The utility of fetal fibronectin in the prediction and prevention of spontaneous preterm birth. Rev Obstet Gynecol. 2008. PMID: 19015761; Lockwood C, et al. Recent advances in elucidating the pathogenesis of preterm delivery, the detection of patients at risk, and preventative therapies. Curr Opin Obstet Gynecol. 1994.
10. Iams JD, Casal D, McGregor JA, et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol. 1995;173:141–145. doi: 10.1016/0002-9378(95)90182-5; Peaceman AM, Andrews WW, Thorp JM, et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol. 1997;177:13–18. doi: 10.1016/s0002-9378(97)70431-9
11. Saade GR, Boniface JD, et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol. 2016;214:633.e1-24. doi: 10.1016/j.ajog.2016.02.001 (PAPR study)